WINNIPEG, MANITOBA--(Marketwire - October 15, 2007) - Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to update the Company’s shareholders on its prostate cancer diagnostic.
